The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Reducing chemotherapy in DLBCL: FLYER results
Viola Poeschel, MD, of the Saarland University Medical School, Homburg, Germany, discusses the results of the Phase III FLYER study (NCT00278421), from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. This revealed that 4 cycles of CHOP plus 6 applications of rituximab to young, favorable-prognosis diffuse large B-cell lymphoma patients was non-inferior to the standard of 6 cycles of CHOP and 2 applications of rituximab; sparing the need for excessive chemotherapy. Dr Poeschel also discusses further research in this area.
